TriangleValganciclovir (NCT07383649)
Valganciclovir trial for Brain Cancer Metastatic (NCT07383649). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for English-speaking adults over 18 with breast cancer, progressive brain metastases, and positive CMV blood testing. At least one progressive brain lesion must remain untreated by radiation.
The idea: valganciclovir blocks viral DNA replication. Researchers test whether adding this antiviral to standard cancer care affects brain-tumor response. Oral treatment is twice daily for two weeks, then a lower dose for four weeks. Scans, blood tests, and thinking tests track response and safety.
This phase 2 study plans 28 patients. Akshjot Puri leads at Houston Methodist, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.